Cobra venom factor: improved method for purification and biochemical characterization - PubMed (original) (raw)
Cobra venom factor: improved method for purification and biochemical characterization
C W Vogel et al. J Immunol Methods. 1984.
Abstract
A method to purify cobra venom factor (CVF) from cobra venom by sequential column chromatography is described which yields a product virtually free of phospholipase A2, a common contaminant of CVF preparations. The separation of phospholipase A2 from CVF was achieved by chromatography on Cibacron blue-agarose, a resin that tightly binds cobra venom phospholipase A2. A rapid and simple hemolytic assay for the qualitative and quantitative determination of CVF based on its ability to induce bystander lysis of erythrocytes has been devised. CVF was isolated from the venom of the Naja naja kaouthia subspecies and some of its biochemical properties and physicochemical parameters were delineated.
Similar articles
- Characterization of the anticoagulants from Taiwan cobra (Naja naja atra) snake venom.
Teng CM, Kuo YP, Lee LG, Ouyang CH. Teng CM, et al. Toxicon. 1987;25(2):201-10. doi: 10.1016/0041-0101(87)90242-x. Toxicon. 1987. PMID: 3576637 - Affinity chromatography of phospholipase A2 from Naja naja naja (Indian cobra) venom.
Hazlett TL, Dennis EA. Hazlett TL, et al. Toxicon. 1985;23(3):457-66. doi: 10.1016/0041-0101(85)90029-7. Toxicon. 1985. PMID: 3927524 - A one-step isolation procedure for phospholipase A2-free cobra venom factor by fast protein liquid chromatography.
Beukelman CJ, Aerts PC, Van Dijk H, Willers JM. Beukelman CJ, et al. J Immunol Methods. 1987 Feb 26;97(1):119-22. doi: 10.1016/0022-1759(87)90113-x. J Immunol Methods. 1987. PMID: 3819435 - Purification and characterization of a neurotoxic phospholipase A2 from Indian cobra (Naja naja naja) venom.
Bhat MK, Prasad BN, Gowda TV. Bhat MK, et al. Toxicon. 1991;29(11):1345-9. doi: 10.1016/0041-0101(91)90121-7. Toxicon. 1991. PMID: 1814010
Cited by
- Differences in uptake of mycobacteria by human monocytes: a role for complement.
Swartz RP, Naai D, Vogel CW, Yeager H Jr. Swartz RP, et al. Infect Immun. 1988 Sep;56(9):2223-7. doi: 10.1128/iai.56.9.2223-2227.1988. Infect Immun. 1988. PMID: 3137162 Free PMC article. - Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ. Meri S, et al. Immunology. 1990 Sep;71(1):1-9. Immunology. 1990. PMID: 1698710 Free PMC article. - Depletion of Complement Enhances the Clearance of Brucella abortus in Mice.
González-Espinoza G, Barquero-Calvo E, Lizano-González E, Alfaro-Alarcón A, Arias-Gómez B, Chaves-Olarte E, Lomonte B, Moreno E, Chacón-Díaz C. González-Espinoza G, et al. Infect Immun. 2018 Sep 21;86(10):e00567-18. doi: 10.1128/IAI.00567-18. Print 2018 Oct. Infect Immun. 2018. PMID: 30082480 Free PMC article. - Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model.
Wang SY, Veeramani S, Racila E, Cagley J, Fritzinger DC, Vogel CW, St John W, Weiner GJ. Wang SY, et al. Blood. 2009 Dec 17;114(26):5322-30. doi: 10.1182/blood-2009-01-200469. Epub 2009 Oct 5. Blood. 2009. PMID: 19805620 Free PMC article. - Molecular cloning and derived primary structure of cobra venom factor.
Fritzinger DC, Bredehorst R, Vogel CW. Fritzinger DC, et al. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12775-9. doi: 10.1073/pnas.91.26.12775. Proc Natl Acad Sci U S A. 1994. PMID: 7809120 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources